Publications by authors named "Eric Refsland"

Claim this Profile
L
Leveraging Implementation Science to End the HIV Epidemic in the United States: Progress and Opportunities for Federal Agencies.
Christopher Gordon, Linda J Koenig, Demetrios Psihopaidas, Eric Refsland, Rebecca Mandt

J Acquir Immune Defic Syndr· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Supplemental Issue of the Journal of the Acquired Immune Deficiency Syndromes (JAIDS): The Centers for AIDS Research (CFAR) Diversity, Equity, and Inclusion Pathway Initiative (CDEIPI).
Alan E Greenberg, Anthony K Wutoh, Lisa Bowleg, Manya Magnus, Brandi Robinson, Eric Refsland

J Acquir Immune Defic Syndr· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Centers for AIDS Research (CFAR) Diversity, Equity, and Inclusion Pathway Initiative (CDEIPI): Developing Career Pathways for Early-Stage Scholars From Racial and Ethnic Groups Underrepresented in HIV Science and Medicine.
Alan E Greenberg, Anthony Wutoh, Lisa Bowleg, Brandi Robinson, Manya Magnus, Eric Refsland

J Acquir Immune Defic Syndr· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glycan-dependent HIV-specific neutralizing antibodies bind to cells of uninfected individuals.
Jana Blazkova, Eric W Refsland, Katherine E Clarridge, Victoria Shi, J Shawn Justement

J Clin Invest· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highlights from the Fourth Biennial Strategies for an HIV Cure Meeting, 10-12 October 2018, Bethesda, MD, USA.
Lillian Kuo, Diane Lawrence, David McDonald, Eric Refsland, Sandra Bridges

J Virus Erad· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals.
Katherine E Clarridge, Jana Blazkova, Kevin Einkauf, Mary Petrone, Eric W Refsland

PLoS Pathog· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection.
Michael C Sneller, J Shawn Justement, Kathleen R Gittens, Mary E Petrone, Katherine E Clarridge, Eric W Refsland

Sci Transl Med· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption.
Katharine J Bar, Michael C Sneller, Linda J Harrison, J Shawn Justement, Edgar T Overton, Eric W Refsland

N Engl J Med· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity.
Eric W Refsland, Judd F Hultquist, Elizabeth M Luengas, Terumasa Ikeda, Nadine M Shaban

PLoS Genet· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The APOBEC3 family of retroelement restriction factors.
Eric W Refsland, Reuben S Harris

Curr Top Microbiol Immunol· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
APOBEC3B is an enzymatic source of mutation in breast cancer.
Michael B Burns, Lela Lackey, Michael A Carpenter, Anurag Rathore, Allison M Land, Eric W Refsland

Nature· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n.
Eric W Refsland, Judd F Hultquist, Reuben S Harris

PLoS Pathog· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1.
Judd F Hultquist, Joy A Lengyel, Eric W Refsland, Rebecca S LaRue, Lela Lackey

J Virol· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction.
Eric W Refsland, Mark D Stenglein, Keisuke Shindo, John S Albin, William L Brown

Nucleic Acids Res· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative proteomics reveals myosin and actin as promising saliva biomarkers for distinguishing pre-malignant and malignant oral lesions.
Ebbing P de Jong, Hongwei Xie, Getiria Onsongo, Matthew D Stone, Xiao-Bing Chen, Eric W Refsland

PLoS One· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interactions among DNA ligase I, the flap endonuclease and proliferating cell nuclear antigen in the expansion and contraction of CAG repeat tracts in yeast.
Eric W Refsland, Dennis M Livingston

Genetics· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis